Best Compound Decision Guides
Research-focused decision guides that aggregate compound comparisons, dosing protocols, and head-to-head data to answer the "what should I use?" question for common research goals.
What These Guides Cover
Each decision guide is structured around a specific research question rather than a single compound. They pull data from ASCEND's compound database, head-to-head comparison pages, and published trial endpoints to surface the tradeoffs that actually matter for a given goal.
The format is consistent across guides: a summary table comparing key metrics, a plain-language decision tree that walks through the most common decision points, and links to the individual compound pages for deeper reference.
GLP-1 Weight Loss Drugs
The GLP-1 category has expanded rapidly. Semaglutide (Wegovy, Ozempic) was the first widely adopted weekly injectable, achieving 15% body weight loss at 68 weeks in STEP-1. Tirzepatide (Zepbound, Mounjaro) added GIP dual agonism and hit 22.5% in SURMOUNT-1. Retatrutide adds glucagon to the triple agonist mechanism and showed 24.2% at 48 weeks in phase 2. CagriSema stacks semaglutide with amylin analog cagrilintide and has shown 22.7% in REDEFINE-1 interim data.
The decision between these compounds depends less on raw efficacy (they all produce substantial weight loss at max dose) and more on tolerability, titration complexity, injection frequency, and cost.
TRT Formulations
Testosterone replacement therapy formulation choice affects injection frequency, peak-to-trough variation, compliance, and practicality. Testosterone cypionate and enanthate (intramuscular or subcutaneous weekly) are the most common research-use options due to cost and availability. Xyosted (subcutaneous testosterone enanthate auto-injector) reduces injection site reactions for some users but costs more. Pellets (Testopel) offer 3-6 month dosing intervals but cannot be adjusted or removed easily once implanted.
Key decision factors: injection frequency tolerance, estradiol management requirements, access to monitoring labs, and whether the user has prior TRT experience.
Recovery Peptides
Recovery peptide selection depends on injury type and location. BPC-157 (Body Protection Compound 157) is the most studied peptide for gut and connective tissue repair and has shown efficacy in rodent models of tendon, muscle, and ligament injury when injected locally or systemically. TB-500 (Thymosin Beta-4 fragment) acts via actin upregulation and is more commonly used for systemic recovery and cardiac/nerve repair models. GHK-Cu adds copper peptide collagen synthesis signaling and is used for skin and wound healing.
For most acute tendon or joint injuries in research contexts, BPC-157 local injection plus TB-500 systemic is the most commonly cited stack protocol. For post-surgical recovery, the addition of GHK-Cu or Thymosin Alpha-1 (immune modulation) is sometimes used.